TRIM36: A Potential Drug Target and Biomarker for ALS (G55521)

Target Name: TRIM36

NCBI ID: G55521

TRIM36

TRIM36: A Potential Drug Target and Biomarker for ALS

Acidic sponges, also known as amyloidosis sponges, are a type of extracellular matrix protein that are found in various tissues throughout the body, including the brain. These sponges are composed of a network of interconnected fibers that are arranged in a repeating pattern of hexagonal rings. One of the unique features of acidic sponges is their ability to engulf and destroy foreign particles, such as viruses and bacteria, which can accumulate in the brain and contribute to the development of a variety of neurological disorders, including Alzheimer's disease (ALS).

Recent studies have identified TRIM36, a protein that is expressed in high levels in the brains of individuals with ALS, as a potential drug target and biomarker for this disease. TRIM36 has been shown to interact with a variety of ALS-associated proteins, including the neurotransmitter glutamate, which is known to play a role in the progression of ALS.

The discovery of TRIM36 as a potential drug target and biomarker for ALS has important implications for the treatment of this progressive neurodegenerative disease. Currently, there are no approved disease-modifying therapies for ALS, and the disease is often treated with supportive care and pain management. However, by targeting TRIM36, researchers may be able to develop new treatments that can slow the progression of ALS and improve quality of life for affected individuals.

In addition to its potential as a drug target, TRIM36 has also been shown to be a potential biomarker for ALS. The protein is expressed in high levels in the brains of individuals with ALS, and its levels have been used as a biomarker to diagnose the disease. This is important because TRIM36 levels can be affected by a variety of factors, including age, gender, and the presence of other neurological disorders, which can affect its expression.

The ability to use TRIM36 as a biomarker for ALS has important implications for the diagnosis and treatment of this disease. Currently, there are no approved disease-modifying treatments for ALS, and the disease is often treated with supportive care and pain management. By using TRIM36 as a biomarker, researchers may be able to identify individuals who are most likely to respond to a drug treatment, or who may be at risk for the disease.

In conclusion, TRIM36 is a protein that has been identified as a potential drug target and biomarker for ALS. Its interaction with ALS-associated proteins, including glutamate, makes it an attractive target for drug development. Furthermore, its potential as a biomarker for ALS has important implications for the diagnosis and treatment of this progressive neurodegenerative disease. Further research is needed to fully understand the role of TRIM36 in ALS and to develop effective treatments.

Protein Name: Tripartite Motif Containing 36

Functions: E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins. Involved in chromosome segregation and cell cycle regulation (PubMed:28087737). May play a role in the acrosome reaction and fertilization

The "TRIM36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets